A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The company is excluding data from the affected sites to maintain the study's integrity
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Subscribe To Our Newsletter & Stay Updated
